Please login to the form below

Not currently logged in
Email:
Password:

heart failure therapy

This page shows the latest heart failure therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis’ heart failure drug Entresto proves superior to enalapril

Novartis’ heart failure drug Entresto proves superior to enalapril

In the US it is indicated for the treatment of heart failure in patients with systolic dysfunction. ... Though the results are hardly surprising considering Entresto was discovered as the first chronic heart failure therapy to show an improvement over

Latest news

  • NICE says no to AZ and Vifor’s rival hyperkalaemia drugs NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

    Most common in patients with poor kidney function, heart failure or liver disease, hyperkalemia can be fatal, and patients have had few options for treatment until now. ... Hyperkalaemia is also seen in patients taking common medications for heart failure

  • Novartis follows Pfizer and freezes US prices this year Novartis follows Pfizer and freezes US prices this year

    Novartis’decision to keep pricing steady has been helped by a rosy set of second-quarter results, with recent launches Cosentyx (secukinumab) for psoriasis and heart failure therapy Entresto (sacubitril and ... for diffuse large B-cell lymphoma (DLBCL)

  • Novartis negotiates ex-US rights to Spark gene therapy Novartis negotiates ex-US rights to Spark gene therapy

    Gene therapy is a promising new avenue to potentially address this unmet need.”. ... The gains were driven by strong performances from new immunotherapy Cosentyx (secukinumab), which breached the $2bn sales threshold for the year, as well as heart

  • Celixir cleared to start trial of stem cell therapy for heart failure Celixir cleared to start trial of stem cell therapy for heart failure

    Celixir cleared to start trial of stem cell therapy for heart failure. ... Heart failure is still a major cause of death affecting millions of patients worldwide [and] current therapies do not reduce chronic myocardial scarring, diminish disease

  • Alcon spin-out more likely but not imminent, says Novartis Alcon spin-out more likely but not imminent, says Novartis

    Alcon re-emerged as one of the engines of Novartis’growth in the third quarter along with fast-growing psoriasis blockbuster Cosentyx (secukinumab) and heart failure therapy Entresto (sacubitril/valsartan), which

More from news
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Heart failure therapy embarks on a new era. After years of older, generic drugs, now new treatments are showing promising results. ... failure by 18% compared to placebo when given on top of standard HF therapy.

  • Pharma deals in April 2015 Pharma deals in April 2015

    uniQure has licensed its proprietary gene therapy programme for congestive heart failure, that is hoped will restore the heart's ability to synthesise S100A1, a calcium sensor and master regulator of ... to become available for common diseases such as

  • Pharma deals during October 2013 Pharma deals during October 2013

    80. Celladon. Mydicar gene therapy for heart failure (phase IIb). 75. ... 75. Trevena. TRV027, GPCR biased ligand for acute heart failure (phase II).

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    Kapusta had previously served as the gene therapy specialist's interim chief executive since September last year, as well as chief financial officer since January 2015. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics